Video

Dr. Overman on Nivolumab and Ipilimumab in Patients With MSI-H CRC

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses a study examining nivolumab (Opdivo) monotherapy, ipilimumab (Yervoy) monotherapy, and the combination of nivolumab and ipilimumab in patients with high microsatellite instability metastatic colorectal cancer.

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses a study examining nivolumab (Opdivo) monotherapy, ipilimumab (Yervoy) monotherapy, and the combination of nivolumab and ipilimumab in patients with high microsatellite instability (MSI-H) metastatic colorectal cancer (CRC).

Interim results of the CheckMate-142 study show that among patients who received single-agent nivolumab, median progression-free survival (PFS) was approximately 6 months. Additionally, Overman explains, PFS at 12 months was approximately 45%.

In the combination cohort of nivolumab/ipilimumab, preliminary findings show an 80% reduction in tumor size, while monotherapy with ipilimumab demonstrated a 55% reduction in tumor size. However, longer follow-up is needed in the combination cohort to confirm these findings, he adds.

Related Videos
Patrick I. Borgen, MD, chair, Department of Surgery, Maimonides Medical Center; head, Maimonides Breast Center, Maimonides Cancer Center
Patrick I. Borgen, MD, chair, Department of Surgery, Maimonides Medical Center; head, Maimonides Breast Center, Maimonides Cancer Center
Elizabeth A. Brem, MD
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
Sandip P. Patel, MD
Pooja Phull, MD
Bhavana "Tina" Bhatnagar, DO
Ashkan Emadi, MD, PhD
Alexis LeVee, MD